World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
27165
World Ranking
17901
National Ranking
8930

Tito R. Mendoza publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Tito R. Mendoza sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 426 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Tito R. Mendoza D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Tito R. Mendoza sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Tito R. Mendoza is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research contributions span the field of Medicine with a focus on Oncology, Pulmonary and Respiratory Medicine, Genetics, Economics and Econometrics, and Pediatrics, Perinatology and Child Health.

Their main fields of study include:

  • Medicine

Subfields they have extensively contributed to are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Economics and Econometrics
  • Pediatrics, Perinatology and Child Health

The scientist's work largely addresses topics related to cancer research and treatment, including:

  • Cancer survivorship and care
  • Glioma Diagnosis and Treatment
  • Childhood Cancer Survivors' Quality of Life
  • Cancer-related cognitive impairment studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Brain Metastases and Treatment
  • Palliative Care and End-of-Life Issues

Tito R. Mendoza has published multiple papers in well-known venues. Frequent publication outlets for their work include:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • UNC Libraries
  • Cancer Research
  • Clinical Trials

Some recent papers include:

  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), 2020, Clinical Trials
  • Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report, 2020, The Lancet Oncology
  • Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas, 2021, Clinical Cancer Research
  • Shared Decision-Making for Lung Cancer Screening, 2021, CHEST Journal
  • Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies, 2021, Transplantation and Cellular Therapy

Frequent co-authors in their research include:

  • Terri S. Armstrong
  • Elizabeth Vera
  • Charles S. Cleeland
  • Mark R. Gilbert
  • Marta Peñas-Prado

Best Publications

  • The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.

    Tito R. Mendoza;X. Shelley Wang;Charles S. Cleeland;Marilyn Morrissey

  • When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

    Ronald C. Serlin;Tito R. Mendoza;Yoshio Nakamura;Katherine R. Edwards

  • Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory

    Charles S. Cleeland;Tito R. Mendoza;Xin Shelley Wang;Chyi Chou

  • Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain.

    San Keller;Carla M. Bann;Sheri L. Dodd;Jeff Schein

  • Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Ethan Basch;Ethan Basch;Bryce B. Reeve;Sandra A. Mitchell;Steven B. Clauser

  • Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Amylou C. Dueck;Tito R. Mendoza;Sandra A. Mitchell;Bryce B. Reeve

  • Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis

    Tito R Mendoza;Tracy Mayne;Dale Rublee;Charles Cleeland

  • Minority cancer patients and their providers: pain management attitudes and practice.

    Karen O. Anderson;Tito R. Mendoza;Vicente Valero;Stephen P. Richman

  • The Norwegian Brief Pain Inventory Questionnaire: Translation and Validation in Cancer Pain Patients

    Pål Klepstad;Jon Håvard Loge;Petter C Borchgrevink;Tito R Mendoza

  • Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors

    Xin Shelley Wang;Fengmin Zhao;Michael J. Fisch;Ann M. O'Mara

  • The Chinese version of the Brief Pain Inventory (BPI-C) : its development and use in a study of cancer pain

    Xin Shelley Wang;Tito R. Mendoza;Shuo Zheng Gao;Charles S. Cleeland

  • Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial

    Charles S. Cleeland;Xin Shelley Wang;Qiuling Shi;Tito R. Mendoza

  • Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy

    Lajos Pusztai;Tito R Mendoza;James M. Reuben;Monica M. Martinez

  • Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control.

    Karen O. Anderson;Stephen P. Richman;Judith Hurley;Guadalupe Palos

  • The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study.

    Charles S. Cleeland;Fengmin Zhao;Victor T. Chang;Jeff A. Sloan

  • Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module†

    David Rosenthal;Tito R Mendoza;Mark S Chambers;Joshua A. Asper

  • Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer

    Michael J. Fisch;Ju Whei Lee;Matthias Weiss;Lynne I. Wagner

  • Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling

    Charles S. Cleeland;Yoshio Nakamura;Tito R. Mendoza;Katherine R. Edwards

  • Assessing symptom distress in cancer patients. The M.D. Anderson symptom inventory. (The University of Texas M. D. Anderson Cancer Center, Houston, Texas) Cancer 2000;89:1634–1646.

    Charles S. Cleeland;Tito R. Mendoza;Xin Shelley Wang;Chyi Chou

  • When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

    R E Serlin;Rodrigo Y. M. Nakamura;Tito R Mendoza;Andrew K. Edwards

Frequent Co-Authors

Charles S. Cleeland
Charles S. Cleeland The University of Texas MD Anderson Cancer Center
David I. Rosenthal
David I. Rosenthal The University of Texas MD Anderson Cancer Center
Adam S. Garden
Adam S. Garden The University of Texas MD Anderson Cancer Center
Ethan Basch
Ethan Basch University of North Carolina at Chapel Hill
Mark R. Gilbert
Mark R. Gilbert National Institutes of Health
Bryce B. Reeve
Bryce B. Reeve Duke University
Charles Lu
Charles Lu The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Valen E. Johnson
Valen E. Johnson Texas A&M University
Deborah Schrag
Deborah Schrag Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always begin with traditional in-person medical school. Today, there are many online pathways that can help you enter the healthcare field or advance your current career. One popular option is medical billing and coding, which offers a flexible entry point into healthcare administration. Prospective students should carefully consider the medical billing and coding certification cost to ensure the program fits their budget and career goals.

For those interested in patient care, nursing offers a variety of online routes—from LPN and RN degrees to advanced practice roles. If affordability is a concern, research the most affordable online nurse practitioner programs to determine your best path. Many students begin by enrolling in nursing school online, balancing coursework with existing commitments.

For experienced nurses aiming for leadership, academia, or specialized research, pursuing an online nursing doctorate can open doors to the highest levels of practice and impact. Whichever route you choose, online degrees in healthcare continue to expand access and flexibility for tomorrow’s medical professionals.

Best Scientists Citing Tito R. Mendoza

Trending Scientists

Recently Published Articles